Literature DB >> 8998488

Using the SF-36 and Euroqol on an elderly population.

J E Brazier1, S J Walters, J P Nicholl, B Kohler.   

Abstract

An important methodological issue in measuring health-related quality of life is whether instruments such as SF-36 and EQ can be used on an elderly population. This paper aims to test the completion, reliability and validity of the SF-36 and Euroqol on an elderly female population, and to compare them with the OPCS Disability Survey. Three hundred and eighty women aged 75 and over participated in a randomized controlled trial of the use of clodronate provided the sample. As part of the trial, patients were asked to complete the UK SF-36 and Euroqol, and the OPCS disability survey instrument administered by interview in a hospital clinic at baseline. A random subsample of respondents were retested six months later. The SF-36 achieved poorer levels of completion by dimension (68.1%-88.9%) than the OPCS (99.2%) and Euroqol (84%-93.5%) instruments. There were no major floor effects in the distribution of scores, except for the role dimensions of SF-36. Correlation between test-retest were significant for all instruments, but lower for the role dimensions and social functioning of SF-36, and these dimensions also had 95% Cls for the mean differences in excess of 10 points. There was substantial agreement between the three instruments, and evidence for their construct validity against age and recent use of health services. The sensitivities of the instruments were tested through hypothetical changes in health status. There was some evidence of greater sensitivity to lower levels of morbidity in the SF-36. Where brevity is required and the health changes are expected to be substantial, then EQ may be sufficient. For greater sensitivity SF-36 seems to have an advantage, however lower completion rates and problems with consistency suggest it requires adaptation. One solution would be to use interviewer administration. Another would be to change the SF-36 to make it more suitable for use in elderly people, although this may reduce its usefulness as a generic instrument.

Entities:  

Mesh:

Year:  1996        PMID: 8998488     DOI: 10.1007/bf00434741

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  13 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

Review 5.  The Short-Form 36 (SF-36) Health Survey and its use in pharmacoeconomic evaluation.

Authors:  J Brazier
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

6.  The short form 36 health status questionnaire: clues from the Oxford region's normative data about its usefulness in measuring health gain in population surveys.

Authors:  S Ziebland
Journal:  J Epidemiol Community Health       Date:  1995-02       Impact factor: 3.710

7.  The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups.

Authors:  C A McHorney; J E Ware; J F Lu; C D Sherbourne
Journal:  Med Care       Date:  1994-01       Impact factor: 2.983

8.  The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

Authors:  C A McHorney; J E Ware; A E Raczek
Journal:  Med Care       Date:  1993-03       Impact factor: 2.983

9.  Effect sizes for interpreting changes in health status.

Authors:  L E Kazis; J J Anderson; R F Meenan
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

10.  The SF-36 health survey questionnaire: is it suitable for use with older adults?

Authors:  V Hayes; J Morris; C Wolfe; M Morgan
Journal:  Age Ageing       Date:  1995-03       Impact factor: 10.668

View more
  94 in total

Review 1.  A comparative review of generic quality-of-life instruments.

Authors:  S J Coons; S Rao; D L Keininger; R D Hays
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

2.  Is the SF-36 health survey questionnaire suitable as a self-report measure of the health status of older adults with Parkinson's disease?

Authors:  J P Hobson; R J Meara
Journal:  Qual Life Res       Date:  1997-04       Impact factor: 4.147

Review 3.  The development and use of quality-of-life measures to evaluate health outcomes in Japan.

Authors:  Shunichi Fukuhara; Naoki Ikegami; George W Torrance; Shuzo Nishimura; Michael Drummond; François Schubert
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery.

Authors:  Elena Losina; James Wright; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2012-03-21       Impact factor: 5.284

5.  Responsiveness of the Short Musculoskeletal Function Assessment (SMFA) in patients with femoral neck fractures.

Authors:  Carl Johan Hedbeck; Jan Tidermark; Sari Ponzer; Richard Blomfeldt; Gunnar Bergström
Journal:  Qual Life Res       Date:  2010-11-12       Impact factor: 4.147

Review 6.  Quality of life in older people: a structured review of generic self-assessed health instruments.

Authors:  K L Haywood; A M Garratt; R Fitzpatrick
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

7.  Functional status, health problems, age and comorbidity in primary care patients.

Authors:  M Wensing; E Vingerhoets; R Grol
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

8.  Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Authors:  Katia Noyes; Andrew W Dick; Robert G Holloway
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 9.  Health related quality of life outcome instruments.

Authors:  Gunnar Németh
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

10.  Development of the WHOQOL-old module.

Authors:  Mick Power; Kathryn Quinn; Silke Schmidt
Journal:  Qual Life Res       Date:  2005-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.